Comment on: European Heart Journal global spotlight on European Medicines Agency evaluation of mavacamten.

The document is a comment on the European Medicines Agency's evaluation of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The author expresses concern about the EMA's interpretation of the benefits of mavacamten on patients' health status. They argue that the clinical trials reviewed by the EMA used the Kansas City Cardiomyopathy Questionnaire (KCCQ) to measure health status, and that a 5-point change in the KCCQ score is considered small but clinically important. The author believes that a larger proportion of patients experienced clinically important improvements in symptoms, function, and quality of life when treated with mavacamten. [Extracted from the article]